摘要
目的:评价应用保列治(5α-睾酮还原酶抑制剂)与哈乐(α1 a受体阻断剂)治疗前列腺增生症(BPH)的临床疗效。方法:对220例前列腺增生症患者随机分成两组:哈乐组(n=112,0.2 mg/d)与保列治组(n=112,0.2 mg/d),依据治疗前后AUA症状评分、最大尿流率(Qm ax)及前列腺体积变化情况进行疗效评估。结果:治疗12周后,哈乐组54.5%的患者AUA症状评分值下降,保列治组54.6%的患者AUA症状评分值下降,两者无统计学差异(P>0.05);治疗24周后,哈乐组64.3%的患者AUA症状评分值下降,保列治组79.6%的患者AUA症状评分值下降,保列治组疗效明显高于哈乐组(P<0.05)。两组患者治疗后较治疗前平均最大尿流率均明显增加,且与治疗时间成正比。两组患者均未观察到明显的前列腺体积变化。结论:保列治与哈乐均能有效改善BPH患者症状及尿流率,临床疗效各有优缺点。
Objective To evaluate the therapeutic effect of harnal and proscar in treating benign prostatic hyperplasia （BPH）. Methods Two hundreds and twenty-two patients with BPH were randomly assigned into 2 groups ： harnal （0.2 mg/d） group （ n=112 ） and proscar （5 mg/d） group （ n=108 ）. American Urologic Association Symptom Index （AUA-SI） scores, the maximal urinary flow rate （Qmax） and prostatic volume were analyzed in the 2 groups. Results After 12 weeks of treatment, 54.5% of the harnal group improved in AUA-SI score; 54.6% of the proscar group improved in AUA-SI score; and there was no significant difference between the 2 groups （P〉0.05）. After 24 weeks of treatment, the proscar group （79.6%） had a greater improvement in AUA-SI score than the harnal group （64.3%） （P〈0.05） ; Qmax in the 2 groups was significantly increased than that before the treatment, and it is proportional to the therapeutic time. The prostatic volume in 2 groups had no significant change. Conclusion Harnal and proscar can significantly improve BPH symptoms and the urinary flow rate. The therapeutic effect of harnal and proscar has their own characteristics.
出处
《中南大学学报（医学版）》
CAS
CSCD
北大核心
2005年第6期708-710,共3页
Journal of Central South University ：Medical Science
关键词
前列腺增生症
药物治疗
治疗效果
benign prostatic hyperplasia
medical therapy： therapeutic effect
